GS-441524
Remdesivir parent nucleoside · Remdesivir nucleoside · GS
Last updated
At a glance
Overview
GS-441524 is the parent nucleoside of remdesivir — the same active triphosphate metabolite, delivered orally instead of by IV infusion. It earned its reputation curing feline infectious peritonitis (a previously fatal coronavirus disease) and has since become the gray-market tool of choice in the long-COVID, post-viral fatigue, and longevity communities for knocking down acute +ssRNA viral infections and chasing persistent viral reservoirs.
The appeal is straightforward: a broad-spectrum mechanism (delayed-chain termination of viral RdRp that evades coronavirus exonuclease proofreading), a clean safety profile with no measurable cytotoxicity up to 100 µM in cell culture, no hormonal or HPG-axis activity, and minimal CYP-mediated drug interactions. Unlike Paxlovid it doesn't tangle with ritonavir-style interaction matrices, and unlike molnupiravir it carries no mutagenicity signal.
"GS-441524 was highly efficacious as a treatment for experimental FIP and showed no measurable cytotoxicity in cell culture up to 100 μM." — Murphy et al., Veterinary Microbiology (2018)
What it is not is a performance or aesthetics compound. It does nothing for body composition, sleep, libido, or hormones — anyone layering it into a longevity stack without an acute or post-viral indication will perceive nothing. The use case is narrow but real: short oral courses around acute respiratory infection, and extended protocols targeting post-viral persistence.
The sections below cover the documented GS-441524 dosage ladder (mg/kg, extrapolated from the rigorous feline FIP literature and the Rasmussen first-in-human analysis), oral vs SC vs IV route trade-offs, typical antiviral and long-COVID protocols, sourcing pitfalls (mislabeled "bioavailable equivalent" tablets are the #1 cause of under-dosing), side effect profile, renal contraindications, and the stacking patterns the community actually runs.
How GS-441524 works
Nucleoside Analog Activation to GS-443902#
GS-441524 is a 1′-cyano-substituted adenosine C-nucleoside. It enters cells through nucleoside transporters (ENT1, ENT2, CNT3) and undergoes sequential host-kinase phosphorylation: the rate-limiting monophosphorylation step, then conversion to diphosphate, then to the bioactive triphosphate GS-443902. This intracellular triphosphate is the same active metabolite generated by remdesivir — GS-441524 simply skips the McGuigan prodrug machinery that remdesivir relies on for IV delivery. The practical consequence is that an oral parent nucleoside, dosed at the gram-or-less scale, can load tissues with the same active species that IV remdesivir delivers in a hospital setting.
The triphosphate accumulates intracellularly with a much longer functional half-life than the parent's ~5 h plasma window — PBMC data from feline subjects show GS-443902 persisting at 8–20× viral EC₅₀ for over 24 hours, which is the pharmacological basis for once-daily oral protocols.
Delayed-Chain Termination of Viral RdRp#
GS-443902 competes with ATP at the catalytic site of viral RNA-dependent RNA polymerase (RdRp). Critically, it is a delayed chain terminator rather than an immediate one — once incorporated into the nascent RNA strand, the polymerase adds approximately three more nucleotides before stalling. This delay is the entire trick of the molecule: coronaviruses carry an nsp14 exonuclease that proofreads and excises classical chain terminators, but the position-i+3 stall site is sterically shielded from exonuclease access.
"The active triphosphate form of GS-441524 acts as a delayed chain terminator for SARS-CoV-2 RNA-dependent RNA polymerase, effectively inhibiting viral replication." — Gordon CJ et al., Journal of Biological Chemistry, 2020
This is why GS-441524 retains potency against coronaviruses that defeat earlier-generation nucleoside antivirals, and why the SARS-CoV-2 EC₉₀ sits in the low-µM range despite robust viral proofreading machinery.
Broad-Spectrum Activity Across +ssRNA Viruses#
Because the mechanism targets a conserved polymerase active site rather than a virus-specific surface protein, GS-443902 inhibits a wide range of positive-sense RNA viruses: SARS-CoV-2, SARS-CoV, MERS-CoV, feline coronavirus (FIPV), respiratory syncytial virus, Ebola, Nipah, and — in recent work — multiple lineages of canine distemper virus.
"GS-441524 was highly effective in attenuating the in vitro replication of multiple lineages of canine distemper virus, expanding its broad-spectrum antiviral potential." — Oliver-Guimera A et al., Viruses, 2025
For the post-viral and acute-respiratory use-case, this breadth is the operational point. The compound does not require viral genotyping to deploy — the same protocol applies whether the trigger is a SARS-CoV-2 reinfection, an enterovirus reservoir hypothesis, or an unidentified +ssRNA respiratory pathogen.
Selectivity and Low Cytotoxicity#
The 1′-cyano modification is the structural feature that drives selectivity. Human RNA polymerase II and mitochondrial RNA polymerase incorporate GS-443902 far less efficiently than viral RdRp, and the foundational Murphy/Pedersen work established the practical safety window in cell culture:
"GS-441524 was highly efficacious as a treatment for experimental FIP and showed no measurable cytotoxicity in cell culture up to 100 μM." — Murphy BG et al., Veterinary Microbiology, 2018
That selectivity ratio (sub-µM antiviral EC₅₀, no cytotoxicity at 100 µM) is the reason 84-day continuous-dosing protocols are tolerated in feline subjects without the bone-marrow or hepatic toxicity that limits older nucleoside antivirals. It is also the reason the first-in-human IV dose at 13 mg/kg produced no serious adverse events.
Renal Clearance and the Practical Consequences#
GS-441524 is eliminated almost entirely renally as unchanged drug — it is not a meaningful CYP3A4, CYP2C9, or CYP2D6 substrate, and protein binding is low (free fraction 62–78%).
"GS-441524 exhibited moderate to low clearance, low protein binding, and oral bioavailability ranging from 8.3% in cynomolgus monkeys to 85% in dogs." — Wang AQ et al., Frontiers in Pharmacology, 2022
Two practical consequences fall out of this pharmacology. First, the drug-interaction profile is remarkably clean — unlike Paxlovid, GS-441524 does not require ritonavir boosting and does not collide with the CYP3A4-metabolized compounds common in physique and longevity stacks (statins, certain AAS, finasteride, tadalafil). Second, renal function is the single gating variable: any meaningful reduction in eGFR shifts the PK toward accumulation, which is why subjects with CKD or recent nephrotoxic exposure are excluded from high-dose protocols and why renal labs are the monitoring priority on extended courses.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 2–5 mg/kg | Once daily | Documented entry-level range |
| Mid | 5–10 mg/kg | Once daily | Most commonly studied range |
| High | 10–15 mg/kg | Once daily | Oral protocols are typically split q12h on a fasted stomach. Once-daily dosing is supported by the long intracellular triphosphate half-life. Acute viral courses run 5–10 days; post-viral protocols extend to 14–30 days. |
Cycle length & outcomes
Documented cycle
1–12 weeks
Plateau after
12 wks
Cycle Length & Protocol Structure#
GS-441524 is dosed by indication and duration of viral insult, not by training cycle. There is no loading phase, no taper, no PCT, and no endocrine downstream — the protocol simply runs until viral knockdown is achieved or the post-viral protocol completes its planned window.
| Indication | Cycle Length | Daily Dose (oral) |
|---|---|---|
| Prophylactic short course (high-exposure event) | 3–5 days | 100–200 mg |
| Acute respiratory +ssRNA infection (COVID, influenza A) | 5–10 days | 5–10 mg/kg, split q12h |
| Post-viral / long-COVID protocol | 14–30 days | 5–10 mg/kg, split q12h |
| Refractory post-viral with neuro symptoms | 30–60 days | 10–15 mg/kg, split q12h |
| FIP-modeled deep-tissue protocol (advanced) | 84 days | 15 mg/kg, split q12h |
Dosing is weight-based (mg/kg) because the compound is non-hormonal and distributes by volume rather than acting on receptor systems with ceiling effects. The same mg/kg figure applies across the subject pool regardless of sex.
Onset & Time-to-Effect#
Plasma Tmax is ~1–2 h after an oral dose, but the bioactive species is the intracellular triphosphate GS-443902, which accumulates over the first 24–48 h of dosing and persists 8–20× above antiviral EC₅₀ for at least 24 h between doses.
"GS-441524 was highly efficacious as a treatment for experimental FIP and showed no measurable cytotoxicity in cell culture up to 100 μM." — Murphy et al., Veterinary Microbiology (2018)
Practical onset timing:
- Acute viral protocols: symptomatic improvement typically within 48–72 h when initiated inside the 72-hour symptom window. Initiation beyond day 5–7 of symptoms shows progressively weaker effect — the literature consistently rewards early starts.
- Post-viral / long-COVID protocols: subjective response timeline is 2–4 weeks. Users targeting tissue viral reservoirs are running the full 30–60 day window before assessing.
- Neurological-symptom protocols: BBB penetration is limited (~7–21% in feline data), which is why the dose ladder pushes into the 10–15 mg/kg range for neuro-dominant presentations.
Loading, Tapering & Splitting#
No loading dose is used. The 24-hour steady-state intracellular triphosphate accumulation handles this automatically. The first-in-human single 13 mg/kg IV dose was well tolerated with a 4.8 h plasma half-life, confirming the once-daily PK rationale.
"In a first-in-human study, a 13 mg/kg IV dose of GS-441524 was well tolerated, with a terminal plasma half-life of 4.8 hours and a free fraction of 62% in humans." — Rasmussen et al., Pharmacology Research & Perspectives (2022)
No taper is required. GS-441524 has zero endogenous-axis activity — no HPG, HPA, or thyroid involvement. The protocol stops the day it stops.
Splitting q12h vs once-daily: the long intracellular triphosphate half-life supports once-daily dosing, but FIP-derived oral protocols universally split q12h. The reason is oral bioavailability buffering — at ~13–20% human oral F, splitting doses smooths peak/trough plasma curves and reduces the GI-side effects that emerge at the top of the dose range. q12h is the community default for any course running beyond 5 days.
Oral doses are administered fasted with a small water bolus, following the feline oral protocol. The food effect in humans is still under formal study (NCT06274853), but the convention is fasted administration.
On-Cycle Bloodwork#
Light-touch monitoring, modeled on the 84-day feline protocol:
| Window | Panel | Rationale |
|---|---|---|
| Baseline | CMP (creatinine, eGFR, BUN), CBC, ALT/AST | Establish renal floor — GS-441524 is renally cleared |
| Every 4 weeks on long courses | CMP, CBC | Track renal function and any hepatic drift |
| Anytime on combination antiviral protocols | Add LFTs | Particularly when stacked with molnupiravir |
No endocrine panel, no lipid panel, no E2 — none of those systems are touched by this molecule.
The single non-negotiable bloodwork item is renal function. GS-441524 is eliminated almost entirely unchanged via the kidneys, so any subject with a reduced eGFR, recent contrast-imaging exposure, or chronic high-dose NSAID use is not running this at the top of the dose range. This is the hard contraindication on the structured list and it stays hard regardless of how good the antiviral need is.
Sourcing & Dose Verification#
The most common cause of "non-response" in both veterinary and off-label use is mislabeled API content. Black-market FIP tablets labeled "50 mg" frequently contain ~25 mg of actual API, with the vendor labeling by "bioavailable equivalent" rather than mg of compound.
"GS-441524 exhibited moderate to low clearance, low protein binding, and oral bioavailability ranging from 8.3% in cynomolgus monkeys to 85% in dogs." — Wang et al., Frontiers in Pharmacology (2022)
The 10×-spread in interspecies oral bioavailability is why human dose extrapolation needs to be done from the Rasmussen pooled-PK analysis and not from cat mg/kg numbers directly. Vendor cross-checking against independent HPLC results (the FIP communities maintain running batch databases) is the practical way around this. Vet-compounded product from regulated pharmacies (Bova Vet and equivalents) is the cleanest sourcing route where jurisdiction allows.
Standalone vs Stacked Protocols#
GS-441524 runs standalone for acute viral indications. The mechanism is complete on its own — viral RdRp inhibition via delayed chain termination doesn't benefit from a second antiviral with the same target.
"The active triphosphate form of GS-441524 acts as a delayed chain terminator for SARS-CoV-2 RNA-dependent RNA polymerase, effectively inhibiting viral replication." — Gordon et al., Journal of Biological Chemistry (2020)
Combination protocols (with molnupiravir, or with nirmatrelvir/ritonavir as in rescue FIP protocols) are reserved for refractory cases and bring their own toxicity ledger — molnupiravir teratogenicity in particular is the limiting factor for anyone with conception plans.
For long-COVID protocols, the adjacent stack (LDN, nattokinase, CoQ10, methylene blue microdoses) has no PK interaction with GS-441524 and can be run concurrently without dose adjustment. None of those compounds boost or blunt the antiviral mechanism — they're parallel tools in the broader post-viral toolkit.
Protocols stop the day the indication resolves. There is no re-cycle interval and no minimum gap between courses.
Risks & mistakes
Common (most users)#
GS-441524 is one of the cleanest antivirals documented in the literature — Murphy's foundational work showed no measurable cytotoxicity in cell culture up to 100 µM, and the first-in-human 13 mg/kg IV dose was well tolerated.
- Mild nausea or appetite suppression — most common on the upper end of oral dosing (10–15 mg/kg/day). Splitting the daily dose q12h and administering with a small amount of food (despite fasted feline protocols) softens this in human-context use. Drops off after the first 2–3 days as steady-state is reached.
- Loose stool / transient GI irritation — dose-dependent, usually resolves within the first week. Reducing to the next dose band down for 48 hours then retitrating up is the standard adjustment.
- Mild fatigue or "antiviral malaise" during the first 3–5 days of an acute viral protocol — often indistinguishable from the infection itself and typically resolves as viral load drops.
- Bitter taste / oral irritation from compounded tablets or reconstituted powder — coating with a gel cap or pairing with a strong-flavored vehicle handles this.
"GS-441524 was highly efficacious as a treatment for experimental FIP and showed no measurable cytotoxicity in cell culture up to 100 μM." — Murphy et al., Veterinary Microbiology (2018)
Uncommon (dose-dependent or individual)#
- Transient ALT/AST elevations — documented in feline cases on prolonged high-dose courses (84-day protocols at 15–20 mg/kg/day oral). For courses extending beyond 30 days, a CMP at baseline and every 4 weeks catches this; values typically normalize within 2 weeks of cycle end.
- Injection-site reactions (SC route only) — painful injections, sterile abscesses, and ulcerative sores are the single most documented adverse effect in the FIP literature, driven by the low pH and DMSO content of black-market formulations. The mitigation is straightforward: switch to the oral route, or source vet-compounded SC solutions (Bova Vet and equivalents) with proper pH buffering. Rotating sites and warming the solution to body temperature before SC administration both reduce incidence.
- Mild creatinine drift — GS-441524 is almost entirely renally cleared. Subjects with borderline renal function or recent NSAID use can show small upward creatinine movement on long courses. Baseline + 4-week eGFR/creatinine on any protocol >2 weeks is the protocol standard.
- Headache or mild dizziness — reported anecdotally at 10+ mg/kg/day, not well characterized in the literature. Splitting q12h and ensuring adequate hydration resolves most cases.
Rare but serious#
- Accumulation toxicity in undiagnosed renal impairment — the mechanism is renal clearance, not hepatic metabolism, so an unrecognized CKD baseline is the dominant rare-but-serious risk. Warning signs: oliguria, ankle edema, rising creatinine, fatigue out of proportion to the infection. Stop the protocol and reassess renal panel.
- Severe injection-site ulceration progressing to abscess (SC route) — almost exclusively a vehicle/excipient problem rather than an API problem. If a SC site shows induration >3 cm, persistent erythema beyond 72 hours, or fluctuance, the protocol switches to oral immediately.
- Hypersensitivity reaction — extremely rare; no published cases in the human or feline literature, but mechanistically possible with any small molecule. Rash, facial swelling, or bronchospasm onset within hours of a dose is a hard stop.
Hard contraindications#
- Pregnancy and lactation. No human reproductive toxicity data exist. Although the animal signal is much milder than molnupiravir's, the absence of data is itself the contraindication. Anyone pregnant, planning conception in the cycle window, or breastfeeding does not run this compound.
- Renal impairment (eGFR <60 mL/min/1.73m²). GS-441524 is eliminated almost entirely as unchanged drug via the kidneys. Reduced GFR causes accumulation; no dose-adjustment data exist.
- Concurrent nephrotoxic agents. High-dose NSAIDs, IV contrast within 48 hours, aminoglycoside antibiotics, cyclosporine, and high-dose tenofovir disoproxil all stack renal load. Either the GS-441524 protocol waits, or the other agent does.
- Co-administration with molnupiravir in anyone with conception plans — the contraindication is on the molnupiravir side (mutagenicity and teratogenicity), but the combination protocol is the typical context in which it arises.
Gender, pregnancy, and PCT considerations#
GS-441524 has no androgen, estrogen, progestin, or HPG-axis activity. There is no virilization risk, no menstrual disruption, no PCT requirement, no aromatase or 5-alpha-reductase interaction. Dosing is weight-based (mg/kg) and identical across the subject pool — male and female protocols are the same.
The single gender-specific consideration is pregnancy and lactation, listed above as a hard contraindication. Subjects with conception plans within the cycle window default to deferring the protocol until after the relevant pregnancy decision point. Outside that one window, the compound is one of the more sex-agnostic tools in the broader peptide and small-molecule toolkit.
"In a first-in-human study, a 13 mg/kg IV dose of GS-441524 was well tolerated, with a terminal plasma half-life of 4.8 hours and a free fraction of 62% in humans." — Rasmussen et al., Pharmacology Research & Perspectives (2022)
FAQ — GS-441524
Research & citations
5 studies cited on this page.
Conclusion
GS-441524 stands out as a gold-standard oral antiviral in the research toolkit, with broad-spectrum activity and the cleanest safety profile in its class. Effective dosing depends on bodyweight, route, and accurate product labeling — but established community protocols handle most edge cases.
Key takeaways:
- Standard dose: 5–10 mg/kg/day oral, typically split q12h on a fasted stomach
- Protocol length: 5–10 days for acute viral protocols, 10–30 days for post-viral/long-COVID research, up to 12 weeks in veterinary precedent
- Oral route is preferred for practicality; SC is more bioavailable but mainly used in veterinary protocols
- Stacking: usually stand-alone; typical community stacks for post-viral use are supportive only (LDN, CoQ10, etc.) with no reported PK interactions
- Headline benefit: potent, direct inhibition of viral replication with minimal side effects and no endocrine disruption or PCT requirements
- Hard contraindications: renal impairment, pregnancy/lactation, co-administration with nephrotoxic drugs
When sourcing is reliable and PK principles are respected, GS-441524 is among the most targeted research antivirals for acute and post-viral protocols.